Annual report pursuant to Section 13 and 15(d)

Accrued Expenses and Other Liabilities

v3.22.0.1
Accrued Expenses and Other Liabilities
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities

Note 7 – Accrued Expenses and Other Liabilities

 

Accrued expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2021 and 2020 (in thousands):

 

      2021       2020  
    As of December 31,  
    2021     2020  
Payroll and incentives   $ 1,343     $ 1,094  
General and administrative expenses     195       280  
Research and development expenses     381       778  
Deferred revenue and other deferred liabilities *     932       643  
Total   $ 2,851     $ 2,795  

 

* At December 31, 2021, the balance included approximately $899 thousand related to the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech feasibility study agreement. At December 31, 2020, the balance included approximately $577 thousand related to the CFF Agreement’s deferred liability and approximately $67 thousand of deferred revenue related to the Genentech feasibility study agreement.